AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04446533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with a placebo product by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of the placebo product will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Study NCT03558594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Behavioral Condition
Study NCT03558594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Behavioral Condition
Study NCT03027154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 in left arm and TB-PPD in right arm
Description: All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
Study NCT03027154 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ESAT6-CFP10 in right arm and TB-PPD in left arm
Description: All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
Study NCT01803568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks of exercise; 4 times pr week
Study NCT01195285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Incision Laparoscopic Surgery cholecystectomy
Description: Laparoscopic Cholecystectomy
Study NCT01195285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Laparoscopic Cholecystectomy (TLC)
Description: Laparoscopic Cholecystectomy
Study NCT01590017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01590017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study NCT03363763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 0.2%
Description: Ointment for topical administration hs x 12 weeks
Study NCT03363763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus 0.4%
Description: Ointment for topical administration hs x 12 weeks
Study NCT03363763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment comparator for topical administration hs x 12 weeks
Study NCT00657670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ready-made spectacles
Description: Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
Study NCT00657670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
Study NCT03616197 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingival graft
Description: A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
Study NCT00871780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Study NCT00875654 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke
Study NCT01607554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician
Study NCT02372656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
Study NCT02372656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Metformin
Description: 1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
Study NCT02372656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.2% Simvastatin
Description: 1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
Study NCT04278157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socio-Cognitive Behavioral Therapy for Suicidal Behavior (SCBT-SB)
Description: The SCBT-SB is a manualized and flexible intervention that uses a modular approach to the treatment of adolescent suicidality. After the first mandatory module (Crisis module), and at the end of each subsequent module, the therapist works with the teen and caregivers to determine the next one. The Crisis Module is fixed and represent the intervention core skills with 9 sessions. The optional coping skills modules include Thoughts, Emotional Regulation, Family Communication, Social Interaction, Activity, Trauma, and Substance Use.
Study NCT04278157 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Therapy that typically consist of eclectic individual therapy including CBT, emphasizing psychoeducation and providing support, with occasional conjoint parent sessions or individual caregiver sessions. The treatment as usual primarily focuses on generating solutions to the adolescent and caregivers most urgent concerns.
Study NCT02521311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine
Description: 12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
Study NCT02521311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
Study NCT01925287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: 500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
Study NCT01925287 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
Study NCT00319839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 260 mg/m2 IV over 30 minutes every 3 weeks
Study NCT00319839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
Study NCT04647643 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel to treat peripheral arterial disease
Study NCT02682524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac 100mg tab.
Study NCT01577745 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0639
Description: MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
Study NCT03375216 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
Study NCT03375216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
Study NCT03375216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sensory testing (Heat, cold, and pressure)
Description: sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
Study NCT03375216 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
Study NCT03375216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
Study NCT03375216 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promis Survey
Description: PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
Study NCT01990209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Study NCT03910244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide Oral Product
Description: Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific adverse event (AE) criteria.
Study NCT01131234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT01131234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT01131234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01131234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04537182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery
Description: Lung volume reduction by surgery
Study NCT04537182 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic lung volume reduction with valves
Description: Lung volume reduction with endobronchial valves.
Study NCT03910244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo will be given.
Study NCT00821795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH/Regular 70/30 mix
Description: injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
Study NCT00821795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart protamine/insulin aspart 70/30 mix
Description: injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
Study NCT02636595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study NCT01952223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel administered at 25 mg/m² as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
Study NCT01952223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy
Description: Prostate+pelvic RT (2 Gy fractions, 5 times per week):~* Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy
Study NCT01952223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prostate radiotherapy
Description: Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy
Study NCT01952223 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: prostate radiotherapy
Description: Prostate-only RT (2 Gy fractions, 5 times per week):~* Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~* Phase 2: prostate-only boost (EBRT) up to 74-78 Gy
Study NCT03561012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-Based Goals and Incentives
Description: The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
Study NCT03561012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Standard of care
Study NCT02963103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral
Study NCT01147237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracoronary stent implantation
Description: Everolimus-eluting stent implantation in patients with long coronary artery disease
Study NCT01778023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
Study NCT01778023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
Study NCT03875846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoperative Hemodynamic Pressures
Description: Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
Study NCT03875846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Flow Rate
Description: A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
Study NCT02934425 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined carbohydrate-rich breakfast
Description: Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
Study NCT02773836 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
Study NCT00509964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
Study NCT00509964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ILF
Description: Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
Study NCT00099736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Description: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
Study NCT00099736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Description: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
Study NCT02934425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High pork protein breakfast
Description: High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
Study NCT04580966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR) workshop
Description: The IBSR intervention workshop included weekly group meetings (3.5 hours/meeting) for 12 weeks. During the workshop, participants were encouraged to identify and inquire their stressful thoughts. Using self-inquiry practices participants were taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants took an active role in investigating their stressful thoughts, and by this regulated their stress and managed symptoms and emotions, thus enabled them to cope better with the psycho-social consequences of the stuttering.
Study NCT02113930 — intervention group
Intervention type: BIOLOGICAL
Intervention: Constitution of a biobank of frozen cells, plasma and serum samples
Description: Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
Study NCT02113930 — intervention group
Intervention type: GENETIC
Intervention: Genetic study
Description: High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
Study NCT04076839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
Study NCT03488433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abduction brace
Description: Donjoy Ultrasling IV
Study NCT03713736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cervical smear
Description: Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
Study NCT03488433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antirotation sling
Description: Donjoy shoulder immobilizer
Study NCT01122862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% chlorhexidine mouthrinse
Description: commercially available 0.12% chlorhexidine mouthrinse